What are the indications for desmopressin 0.1 µg/kg?

Indications for Desmopressin 0.1 mcg/kg

Desmopressin at 0.1 mcg/kg is not a standard dosing regimen for any approved indication. The FDA-approved dose for hemophilia A and von Willebrand disease is 0.3 mcg/kg IV, while other indications use fixed oral dosing or weight-based subcutaneous/IV dosing for diabetes insipidus 1.

FDA-Approved Indications (Standard Dosing)

Hemophilia A and von Willebrand Disease Type I

• Standard dose: 0.3 mcg/kg IV infused over 15-30 minutes 1
• Indicated for hemophilia A patients with factor VIII levels >5% 1
• Indicated for mild to moderate von Willebrand disease Type I with factor VIII levels >5% 1
• Administered 30 minutes prior to surgical procedures or for spontaneous/trauma-induced bleeding episodes 1
• Not indicated for severe von Willebrand disease, hemophilia B, or patients with factor VIII antibodies 1
• Preoperative administration may be useful for patients with von Willebrand disease, hemophilia A, and platelet hemostatic disorders undergoing cardiac surgery 2

Central Diabetes Insipidus

• Standard dose: 0.5-1 mL (2-4 mcg) daily via IV or subcutaneous injection, usually in two divided doses 1
• Indicated for antidiuretic replacement therapy in central (cranial) diabetes insipidus 1
• Indicated for temporary polyuria/polydipsia following head trauma or pituitary surgery 1
• Not effective for nephrogenic diabetes insipidus 1
• Dose must be individually adjusted based on adequate sleep duration and appropriate water turnover 1

Nocturnal Enuresis (Oral Formulations Only)

• Standard dose: 0.2-0.4 mg oral tablets (not weight-based) 2
• Evidence-based therapy (Grade Ia) for monosymptomatic nocturnal enuresis 2
• Most efficient in children with nocturnal polyuria (>130% expected bladder capacity) and normal bladder function (>70% expected bladder capacity) 2
• Approximately 30% achieve complete response, 40% partial response 2
• Contraindication: Polydipsia due to risk of water intoxication and hyponatremia 2
• Nasal spray formulation discouraged due to higher hyponatremia risk 2

Non-Approved/Off-Label Uses

Perioperative Hemostasis

• Not recommended for prophylactic use in cardiac surgery without platelet hemostatic defects 2
• Meta-analyses show no benefit in patients without bleeding disorders 2
• Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists guidelines do not recommend prophylactic DDAVP 2
• Randomized trials in children undergoing cardiac surgery failed to show benefit 2
• May be considered at 0.3 mcg/kg for patients with platelet dysfunction from cardiopulmonary bypass or recent antiplatelet therapy, but evidence certainty is low 2

Adult Nocturia

• Oral formulations (50-75 mcg orally disintegrating tablets) show efficacy in men with nocturia 3
• Lower doses (≤0.2 mg oral) are safe and effective in elderly patients with nocturnal polyuria when closely monitored 4

Critical Safety Considerations

Hyponatremia Risk

• Major safety concern: Water intoxication with hyponatremia and convulsions if combined with excessive fluid intake 2
• Risk factors include extremes of age, existing comorbidity, drug interactions, intranasal formulations, and intercurrent illness 5
• Fluid restriction mandatory: evening intake ≤200 mL (6 ounces) with no drinking until morning 2
• Elderly patients at higher risk; close monitoring required 1, 4
• Hyponatremia incidence approximately 4.4% in elderly with proper education and follow-up 4

Monitoring Requirements

• Blood pressure and pulse during IV infusion 1
• Serum sodium levels at baseline, 3-7 days after starting, then every 3-6 months 4
• Renal function monitoring in elderly patients due to renal excretion 1

Tachyphylaxis

• Repeated administration more frequently than every 48 hours may result in diminished response 1
• Initial response reproducible if 2-3 days between administrations 1

Dosing Clarification

The 0.1 mcg/kg dose mentioned in the question does not correspond to standard clinical practice. If this dose is being considered, it represents approximately one-third of the FDA-approved dose for hemophilia/von Willebrand disease (0.3 mcg/kg) and would likely be subtherapeutic for approved indications 1.